171 related articles for article (PubMed ID: 29600428)
1. CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
Watanabe J; Sato K; Osawa Y; Horiuchi T; Kato S; Hikota-Saga R; Maekawa T; Yamamura T; Kobayashi A; Kobayashi S; Kimura F
Int J Hematol; 2018 Jul; 108(1):47-57. PubMed ID: 29600428
[TBL] [Abstract][Full Text] [Related]
2. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.
Wang J; Liu Y; Li Z; Du J; Ryu MJ; Taylor PR; Fleming MD; Young KH; Pitot H; Zhang J
Blood; 2010 Dec; 116(26):5991-6002. PubMed ID: 20921338
[TBL] [Abstract][Full Text] [Related]
3. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
Javadi M; Richmond TD; Huang K; Barber DL
J Biol Chem; 2013 Jul; 288(27):19459-70. PubMed ID: 23696637
[TBL] [Abstract][Full Text] [Related]
4. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.
Padron E; Painter JS; Kunigal S; Mailloux AW; McGraw K; McDaniel JM; Kim E; Bebbington C; Baer M; Yarranton G; Lancet J; Komrokji RS; Abdel-Wahab O; List AF; Epling-Burnette PK
Blood; 2013 Jun; 121(25):5068-77. PubMed ID: 23632888
[TBL] [Abstract][Full Text] [Related]
5. Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Geissler K; Jäger E; Barna A; Gurbisz M; Graf T; Graf E; Nösslinger T; Pfeilstöcker M; Machherndl-Spandl S; Stauder R; Zebisch A; Sill H; Öhler L; Kusec R; Hörmann G; Valent P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842710
[TBL] [Abstract][Full Text] [Related]
6. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.
Makishima H; Sugimoto Y; Szpurka H; Clemente MJ; Ng KP; Muramatsu H; O'Keefe C; Saunthararajah Y; Maciejewski JP
Leukemia; 2012 Jul; 26(7):1547-54. PubMed ID: 22246246
[TBL] [Abstract][Full Text] [Related]
7. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).
Padron E; Dezern A; Andrade-Campos M; Vaddi K; Scherle P; Zhang Q; Ma Y; Balasis ME; Tinsley S; Ramadan H; Zimmerman C; Steensma DP; Roboz GJ; Lancet JE; List AF; Sekeres MA; Komrokji RS;
Clin Cancer Res; 2016 Aug; 22(15):3746-54. PubMed ID: 26858309
[TBL] [Abstract][Full Text] [Related]
8. Acquired expression of
Nakata Y; Ueda T; Nagamachi A; Yamasaki N; Ikeda KI; Sera Y; Takubo K; Kanai A; Oda H; Sanada M; Ogawa S; Tsuji K; Ebihara Y; Wolff L; Honda ZI; Suda T; Inaba T; Honda H
Blood; 2017 Apr; 129(15):2148-2160. PubMed ID: 28209720
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
[TBL] [Abstract][Full Text] [Related]
11. Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction.
Liu CS; Yang-Yen HF; Suen CS; Hwang MJ; Yen JJ
Sci Rep; 2017 Jul; 7(1):4613. PubMed ID: 28676638
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid-induced modulation of cytokine secretion from normal and leukemic human myelomonocytic cells.
Welker P; Lippert U; Nürnberg W; Krüger-Krasagakes S; Möller A; Czarnetzki BM
Int Arch Allergy Immunol; 1996 Feb; 109(2):110-5. PubMed ID: 8563484
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
[TBL] [Abstract][Full Text] [Related]
14. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
15. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
[TBL] [Abstract][Full Text] [Related]
16. The signal transduction through Grb2/Ash in hematopoietic cells.
Odai H; Hanazono Y; Sasaki K; Iwamatu A; Yazaki Y; Hirai H
Leukemia; 1997 Apr; 11 Suppl 3():405-7. PubMed ID: 9209406
[TBL] [Abstract][Full Text] [Related]
17. Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.
Bunda S; Qin K; Kommaraju K; Heir P; Ohh M
Oncogene; 2015 Feb; 34(6):789-97. PubMed ID: 24469048
[TBL] [Abstract][Full Text] [Related]
18. Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.
Bernard V; Gebauer N; Dinh T; Stegemann J; Feller AC; Merz H
Int J Clin Exp Pathol; 2014; 7(4):1667-76. PubMed ID: 24817963
[TBL] [Abstract][Full Text] [Related]
19. Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder.
Hyakuna N; Muramatsu H; Higa T; Chinen Y; Wang X; Kojima S
Pediatr Blood Cancer; 2015 Mar; 62(3):542-4. PubMed ID: 25283271
[TBL] [Abstract][Full Text] [Related]
20. An acquired G-CSF receptor mutation results in increased proliferation of CMML cells from a patient with severe congenital neutropenia.
Germeshausen M; Schulze H; Kratz C; Wilkens L; Repp R; Shannon K; Welte K; Ballmaier M
Leukemia; 2005 Apr; 19(4):611-7. PubMed ID: 15729385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
